New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 5, 2014
07:11 EDTBMYBristol-Myers key studies still have high chance of success, says JPMorgan
JPMorgan says it still sees a high probability that Bristol-Myers' two key phase III studies of nivolumab in 2nd-line lung cancer hit their endpoints. The firm views the study results as the key catalyst for shares in the next six months, and notes its view is unchanged following this year's American Society of Clinical Oncology meeting. JPMorgan has an Overweight rating on Bristol with a $60 price target.
News For BMY From The Last 14 Days
Check below for free stories on BMY the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 17, 2014
07:43 EDTBMYBofA/Merrill to hold a conference
Subscribe for More Information
September 16, 2014
06:00 EDTBMYBristol-Myers announces Health Canada approval of Yervoy
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use